February 08, 2023
Pulmonx to Report Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023
Media
February 08, 2023
Targovax ASA: Invitation to Targovax’s fourth quarter 2022 presentation, Thursday 16 February
February 07, 2023
Carisma Therapeutics Appoints Moderna CSO of External Research Ventures, Lin Guey, to Scientific Advisory Board
February 01, 2023
Ariceum Therapeutics Appoints Radioligand Expert, Germo Gericke, M.D., as Chief Medical Officer
January 31, 2023
Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board
January 30, 2023
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
January 23, 2023
Priothera announces first patients enrolled in pivotal MO-TRANS global Phase 2b/3 study with mocravimod as an adjunctive and maintenance therapy for patients with Acute Myeloid Leukemia (AML) undergoing allogeneic Hematopoietic Cell Transplant (HCT)
January 11, 2023
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
January 11, 2023
Oncopeptides appoints Holger Lembrer as Chief Financial Officer
January 10, 2023
Hemab Therapeutics Announces First Patient Dosed in Phase 1/2 Study of HMB-001 to Treat Bleeding Disorder Glanzmann Thrombasthenia
